Though 125I-KX1 showed high tumor uptake (~5% ID/g at 2 h p.i), olaparib pre-injection (i.p.)did not reduce tracer accumulation in the tumor, which is the standard way to evaluate PARP specificity. This evidence concerns the gene PARP1 and neoplasm.